Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer

In silico analysis to identify new CD36 inhibitors

To identify new CD36 inhibitors, we screened in silico a commercial library of 30,000 compounds (https://www.hit2lead.com) targeting a protein region around the FA binding site centered at Val142…

Continue Reading